Dextenza

ApprovedSmall molecule

TTufts Medical Center

Dextenza is one of 69 small molecule programs targeting Retinal Detachment. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal DetachmentActive, not recruiting

Eye DiseaseActive, not recruiting

CataractActive, not recruiting

Retinal DetachmentApproved

Active, not recruiting

Eye DiseaseApproved

Active, not recruiting

CataractApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Kenalog

BBausch Health Americas, Inc.

Phase 3

4 2

Clobetasol Propionate

Bayer

Phase 3

3 3

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—4

Dextenza

TTufts Medical Center

Approved

1 5

Mapracorat

Bayer

Phase 3

4 6

KPI-121

KKala Pharmaceuticals, Inc.

Phase 3

1 7

XG-102

XXigen SA

Phase 3

2 8

Midalozam

Idorsia Pharmaceuticals Ltd.

Phase 3

2 9

Zolymbus

AbbVie

Preclinical

—10

Neurontin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dexamethasone2 trials

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

Completed·SSight Medical Doctors PLLC·Phase 4·NCT04168112·20 enrolled

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

Unknown status·NNathan Steinle·Phase 4·NCT04529512·40 enrolled

Prospective1 trial

The PRIME Study: A Randomized, Controlled, Prospective Study

Recruiting·VVance Thompson Vision - MT·Phase 4·NCT04549935·20 enrolled

Retinal Detachment1 trial

Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment

Terminated·MMidwest Eye Institute·Phase 4·NCT04464629·7 enrolled

Cataract1 trial

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

Completed·SSilverstein Eye Centers·Phase 4·NCT04316936·15 enrolled

Eye Disease1 trial

Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)

Terminated·TTufts Medical Center·Phase 4·NCT04527887·54 enrolled

1 more indication

Inflammation1 trial

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

Unknown status·—·Phase 4·NCT05116345·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Dextenza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dextenza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dextenza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tufts Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTufts Medical Center

Dextenza

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dexamethasone2 trials

Prospective1 trial

Retinal Detachment1 trial

Cataract1 trial

Eye Disease1 trial

Inflammation1 trial

References

Drug Info

Quick Facts

Related News